Business
CareDx provides transplant diagnostics, products, digital tools, and specialized services for transplant patients and centers.
CareDx grew FY2025 revenue but swung back to a loss, spent $87.8M on buybacks, and had only insider sales.
The read at a glance✓ Audited against SEC data
- Business mix — Transplant diagnosticsNote
- Revenue — $379.8M, +13.8%OK
- Net income — ($21.4M), lossWatch
- Buybacks — $87.8MWatch
- Equity — $303.1M, -19.9%Watch
- Insiders — 0 purchases and 9 salesWatch
- Accounting — Altman weak; Beneish clean; EQ safeWatch
Where the revenue comes from
Fiscal 2025, as CareDx, Inc. reports it. History and quarterly detail are in the app.
- Testing services revenue$274.5M
- Patient and digital solutions revenue$56.9M
- Product revenue$48.4M
Leadership changes
From CareDx, Inc.'s own filings, the day they're filed.
- Suresh Gunasekaran · director · appointmenteff. 2025-10-22
- Keith Kennedy · Chief Operating Officer · appointmenteff. 2024-09-12
- John W. Hanna · President · appointmenteff. 2024-04-15
Latest filings
- 8-K · Company announcement2026-07-30
- 10-Q · Quarterly report2026-07-30
- 8-K · Company announcement2026-07-07
- 8-K · Company announcement2026-06-15
- 10-Q · Quarterly report2026-04-28
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CareDx, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.